Atossa Therapeutics, Inc (ATOS)

Etorro trading 970x250
Atossa Therapeutics, Inc (ATOS) Logo

About Atossa Therapeutics, Inc

Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company’s lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington. Address: 107 Spring Street, Seattle, WA, United States, 98104

Atossa Therapeutics, Inc News and around…

Latest news about Atossa Therapeutics, Inc (ATOS) common stock and company :

Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month
21 Oct, 2021 Yahoo! Finance

Global Pandemic Caused a Significant Drop In Mammograms as Clinics Remained ClosedSEATTLE, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Dr. Steven Quay, CEO of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today released a short video message recognizing Breast Cancer Awareness Month, an

12 Health Care Stocks Moving In Wednesday's After-Market Session
20 Oct, 2021 FinancialContent

Gainers Tenet Healthcare (NYSE:THC) stock rose 7.06% to $70.3 during Wednesday's after-market session. Today's trading volume for ...

Implied DWAS Analyst Target Price: $104
30 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA SmallCap Momentum ETF (DWAS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $104.08 per unit.

Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia
30 Sep, 2021 FinancialContent

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE

Most Active Penny Stocks to Buy? Check These 4 Out Right Now
23 Sep, 2021 FinancialContent
Hot Penny Stocks on Reddit to Watch Right Now
21 Sep, 2021 FinancialContent
Top Penny Stocks on Reddit For Your Watchlist Right Now
17 Sep, 2021 FinancialContent
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Atossa Therapeutics, Inc. - ATOS
13 Sep, 2021 Yahoo! Finance

New York, New York--(Newsfile Corp. - September 13, 2021) - Levi & Korsinsky announces that it has commenced an investigation of Atossa Therapeutics, Inc. (NASDAQ: ATOS) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/atossa-therapeutics-inc-information-request-form or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.Levi & Kor

Monday's ETF Movers: URA, PTH
13 Sep, 2021 FinancialContent

In trading on Monday, the Uranium ETF is outperforming other ETFs, up about 5.5% on the day. Components of that ETF showing particular strength include shares of Fission 3.0, up about 29.4% and shares of Laramide Resources, up about 22.4% on the day.

3 Hot Penny Stocks For This Week’s Small-Caps Watchlist
12 Sep, 2021 FinancialContent
3 Reasons to Love Atossa Therapeutics Stock
10 Sep, 2021 Yahoo! Finance

Shares of Seattle, Washington-based Atossa Therapeutics (ATOS), a clinical-stage biopharmaceutical company researching treatments for both cancer and Covid-19, soared more than 9 times in value in the first six months of 2021... before abruptly turning tail and losing more than half their value over the last three months. That's bad news for anyone who bought the shares at their peak in mid-June -- but it could be great news for investors who buy Atossa stock today. Or so says Ascendiant analyst

ATOS Stock Holders Should Mark Their Calendars for Oct. 7
10 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, investors in Atossa Pharmaceuticals and ATOS stock appear to be cheering a delayed shareholder vote on a stock issuance proposal. The post ATOS Stock Holders Should Mark Their Calendars for Oct. 7 appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

7 Penny Stocks Waiting on The FDA for Rocket Fuel
09 Sep, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote
07 Sep, 2021 FinancialContent
Noteworthy Thursday Option Activity: ATOS, TPR, FSLR
02 Sep, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Atossa Therapeutics Inc (ATOS), where a total volume of 35,059 contracts has been traded thus far today, a contract volume which is representative of approximately 3.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 57.4% of ATOS's average daily trading volume over the past month, of 6.1 million shares..

Best Penny Stocks to Buy Under $4 on Robinhood? 3 to Watch
02 Sep, 2021 FinancialContent
Atossa To Conduct Endoxifen Mid-Stage Study In Sweden
02 Sep, 2021 FinancialContent

Atossa Therapeutics Inc(NASDAQ: ATOS) hasreceived approvalfrom the Swedish Ethics Review Authority to begin a Phase ...

Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden
02 Sep, 2021 FinancialContent
Atossa Therapeutics Stock Lost Its Covid Mojo, and Its Pipeline Fails To Impress
31 Aug, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Atossa’s COVID-19 treatment is too little too late and I am concerned about the market size for Endoxiden. ATOS stock should not have a $448 million market cap. The post Atossa Therapeutics Stock Lost Its Covid Mojo, and Its Pipeline Fails To Impress appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Atossa Therapeutics Has a Steep Climb Ahead of It
31 Aug, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Atossa Therapeutics is popular with the Reddit crowd. However, ATOS stock doesn’t make the top 25 on the platform. Should you buy it anyway?  The post Atossa Therapeutics Has a Steep Climb Ahead of It appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

As its Meme Status Has Come and Gone, Skip Out on Atossa Therapeutics Stock
30 Aug, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips So, overvalued, with low squeeze odds, what's the best move with ATOS stock? Sell or avoid, before dilution and other factors push it back down to its pre-hype price levels of around $1 per share. The post As its Meme Status Has Come and Gone, Skip Out on Atossa Therapeutics Stock appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Atossa Therapeutics May Look Tempting, but There’s No Reason to Get in Now
30 Aug, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Atossa Therapeutics has made a pivot to assist in the battle to fight Covid-19. But it seems that investors in ATOS stock are finding this to be a message they've already heard. The post Atossa Therapeutics May Look Tempting, but There’s No Reason to Get in Now appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

October 8th Options Now Available For Atossa Therapeutics (ATOS)
26 Aug, 2021 FinancialContent

Investors in Atossa Therapeutics Inc (ATOS) saw new options begin trading today, for the October 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ATOS options chain for the new October 8th contracts and identified one put and one call contract of particular interest.

Sum Up The Parts: PTH Could Be Worth $196
26 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA Healthcare Momentum ETF (PTH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $195.71 per unit.

3 Penny Stocks To Buy For Under $4 On Robinhood
19 Aug, 2021 FinancialContent
3 Biotech Penny Stocks With High Volume To Watch in August
18 Aug, 2021 FinancialContent
7 Reddit Penny Stocks That Are Lighting Up the Internet and the Market
17 Aug, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks are as speculative as investments get, but if you don't mind the risk involved, these seven offer reasons to be interested. The post 7 Reddit Penny Stocks That Are Lighting Up the Internet and the Market appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

With Zero Revenue, I Can’t Get Excited About Atossa
17 Aug, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ATOS stock surged briefly in 2021 based on several catalysts, but none of them right now is supportive of its current price and valuation. The post With Zero Revenue, I Can’t Get Excited About Atossa appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting
13 Aug, 2021 FinancialContent
10 Penny Stocks to Buy to Create a $500 Portfolio
11 Aug, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips These ten low-priced penny stocks have ample room to gain, making them each worthy of a small, speculative investment. The post 10 Penny Stocks to Buy to Create a $500 Portfolio appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Atossa Therapeutics, Inc (ATOS) is a NASDAQ Common Stock listed in , ,

970x250